UNSPSC 51313512: Dimetholizine phosphate

This classification denotes a histamine-1 receptor antagonist C15H24N2O2.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8VNU0OD47W, chemically known as piperazine, 1-(2-methoxyphenyl)-4-(3-methoxypropyl)-, phosphate, but more generally known as dimetholizine phosphate, which bears US NIH Compound Identifier 71586971. Most nations, for tariff and trade purposes, schedule dimetholizine phosphate under HS 29335995 and SITC 51576. As of Q4 2014, DIMETHOLIZINE PHOSPHATE remains US FDA's Preferred Term for this commodity.

SMILES: COCCCN1CCN(CC1)C2CCCCC2OC.OP(=O)(O)O.

UNSPSC 51313512 Dimetholizine phosphate, a Commodity code, shows limited recent state and local procurement activity directly aligned with the code's nominal scope. The three most recent opportunities on file involve naloxone acquisition, a Request for Information on direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical contracting through a cooperative purchasing alliance — none of which specifically reference dimetholizine phosphate. State and local governments buying under this code, when activity occurs, are typically acquiring pharmaceutical products for health departments, county health systems, and multistate cooperative purchasing organizations that distribute to participating state agencies and local facilities. The work involves sourcing branded or generic pharmaceuticals through established wholesaler networks, meeting FDA compliance and cGMP certification requirements, and maintaining supply agreements with defined delivery and pricing structures.

Recent opportunities span Florida (Seminole County's procurement of naloxone and drug deactivation systems via IFB 60459723LAS, due July 26, 2023), Texas (HHS Commission's Request for Information on direct-to-manufacturer prescriptions, HHS0017013, posted April 3, 2026), and a multistate cooperative vehicle centered in Minnesota (MMCAP's RFP S1070000015802 for generic pharmaceuticals and OTC products, due March 26, 2026, spanning Minnesota and Oregon). The MMCAP cooperative represents the largest and most active recent procurement under pharmaceutical commodity codes, requiring vendors to supply through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and accepting multiple contract structures with weighted evaluation favoring price competitiveness (75 percent). The code shows no standout repeat-buyer pattern in recent filings and no explicit set-aside or disadvantaged-enterprise designations across the opportunities listed.